Protalix BioTherapeutics Inc(PLX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PLX Protalix BioTherapeutics Inc

盘后交易 03-24 17:47:21 EDT

2.07

-0.06

-2.82%

盘后2.08

+0.01+0.36%

17:09 EDT

最高2.14	最低2.03	成交量72.91万
今开2.13	昨收2.13	日振幅5.16%
总市值1.66亿	流通市值1.26亿	总股本8,042万
成交额151.05万	换手率1.20%	流通股本6,076万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PLX","market":"US","secType":"STK","nameCN":"Protalix BioTherapeutics Inc","latestPrice":2.07,"timestamp":1774382400000,"preClose":2.13,"halted":0,"volume":729094,"hourTrading":{"tag":"盘后","latestPrice":2.0774,"preClose":2.07,"latestTime":"17:09 EDT","volume":6368,"amount":13179.734975999998,"timestamp":1774386548282,"change":0.0074,"changeRate":0.003575,"amplitude":0.008406},"delay":0,"changeRate":-0.028169014084507067,"floatShares":60755281,"shares":80421181,"eps":-0.08196432,"marketStatus":"盘后交易","change":-0.06,"latestTime":"03-24 17:47:21 EDT","open":2.13,"high":2.14,"low":2.03,"amount":1510455.0719438,"amplitude":0.051643,"askPrice":2.08,"askSize":430,"bidPrice":2.03,"bidSize":246,"shortable":3,"etf":0,"ttmEps":-0.08196432,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774396800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":829022400000,"exchange":"AMEX","adjPreClose":2.13,"preHourTrading":{"tag":"盘前","latestPrice":2.18,"preClose":2.13,"latestTime":"09:25 EDT","volume":2002,"amount":4340.860524,"timestamp":1774358755053,"change":0.05,"changeRate":0.023474,"amplitude":0.011033},"postHourTrading":{"tag":"盘后","latestPrice":2.0774,"preClose":2.07,"latestTime":"17:09 EDT","volume":6368,"amount":13179.734975999998,"timestamp":1774386548282,"change":0.0074,"changeRate":0.003575,"amplitude":0.008406},"volumeRatio":0.461401,"impliedVol":0.3451,"impliedVolPercentile":0.1952},"requestUrl":"/m/hq/s/PLX/tweets","defaultTab":"tweets","newsList":[{"id":"1127056883","title":"Protalix BioTherapeutics公布2025财年业绩 预计2026年营收最高达8300万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127056883","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127056883?lang=zh_cn&edition=full","pubTime":"2026-03-18 19:33","pubTimestamp":1773833591,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics Inc于3月18日公布了2025财年财务及业务业绩。公司预计2026年总营收将在7800万美元至8300万美元之间，这一预测区间较当前市场预期呈现积极增长态势。作为专注于开发基于植物细胞表达技术的重组治疗蛋白的生物制药公司，Protalix的核心产品线包括针对戈谢病等罕见病的酶替代疗法。公司在巴西等新兴市场的商业化布局逐步深化，2025财年业绩为2026年的营收增长奠定了坚实基础。财报公布后，Protalix股价在盘前交易中呈现温和波动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1103227221","title":"欧盟批准凯西与Protalix合作药物Elfabrio新增四周给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1103227221","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103227221?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:16","pubTimestamp":1773054994,"startTime":"0","endTime":"0","summary":"3月9日——凯西全球罕见病公司与Protalix BioTherapeutics Inc共同宣布，欧洲委员会已正式批准其联合研发药物Elfabrio®（pegunigalsidase alfa）新增每四周一次给药方案。\n此次欧盟批准四周给药方案后，Protalix公司将获得来自合作伙伴凯西支付的2500万美元监管里程碑款项。\n此次批准将为患者提供更灵活的治疗选择，标志着该药物在临床应用上的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2610956806","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘快速上涨5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610956806","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610956806?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:33","pubTimestamp":1770820430,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日22时33分，Protalix Biotherapeutics, Inc. 股票出现异动，股价快速上涨5.56%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体跌幅为0.07%。其相关个股中，Quince Therapeutics, Inc.、Pmgc Holdings Inc.、Phio Pharmaceuticals Corp.涨幅较大，Pmgc Holdings Inc.、Quince Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1730.36%、237.44%、176.09%，振幅较大的相关个股有Quince Therapeutics, Inc.、Tuhura Biosciences, Inc.、Kalaris Therapeutics, Inc.，振幅分别为20.05%、15.38%、11.48%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602112233509540c624&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602112233509540c624&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2608133842","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.00%报2.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608133842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608133842?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:00","pubTimestamp":1770130851,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日23时00分，Protalix Biotherapeutics, Inc. 股票出现异动，股价大幅上涨5.00%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为1.00%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Liminatus Pharma, Inc.涨幅较大，Cdt Equity Inc.、Pmgc Holdings Inc.、Liminatus Pharma, Inc.较为活跃，换手率分别为631.66%、578.09%、51.10%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Briacell Therapeutics Corp C/Wts 26/02/2026、Bioatla, Inc.，振幅分别为70.33%、32.58%、24.70%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203230051a6cf0931&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203230051a6cf0931&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"1150104851","title":"Protalix BioTherapeutics 第三季度每股收益为0.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150104851","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150104851?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:40","pubTimestamp":1763574048,"startTime":"0","endTime":"0","summary":"11月13日 - Protalix BioTherapeutics 第三季度税前利润为223.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"1106718567","title":"奇耶斯全球罕见疾病请求欧洲药品管理局对Elfabrio 2 mg/kg每四周给药方案的负面意见进行重新审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1106718567","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106718567?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:30","pubTimestamp":1763569859,"startTime":"0","endTime":"0","summary":"11月3日——奇耶斯全球罕见疾病公司请求欧洲药品管理局（EMA）药物评审委员会（CHMP）对其提出的每四周给药2 mg/kg的Elfabrio方案的负面意见进行重新审查。奇耶斯全球罕见疾病公司和Protalix BioTherapeutics正在向EMA申请重新审查Elfabrio（Pegunigalsidase Alfa）在欧盟的替代给药方案的负面意见。目前Elfabrio的现有市场授权仍然有效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1183889421","title":"Protalix BioTherapeutics 第三季度每股收益为0.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183889421","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183889421?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:09","pubTimestamp":1763035744,"startTime":"0","endTime":"0","summary":"11月13日 - Protalix BioTherapeutics 第三季度税前利润为223.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1189273756","title":"奇耶西全球罕见病公司申请重新审查欧洲药品管理局CHMP对Elfabrio 2 mg/kg每4周给药方案的负面意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1189273756","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189273756?lang=zh_cn&edition=full","pubTime":"2025-11-04 07:47","pubTimestamp":1762213677,"startTime":"0","endTime":"0","summary":"11月3日（路透社） - 奇耶西全球罕见病公司请求重新审查欧洲药品管理局（EMA）药品人用委员会（CHMP）对Elfabrio（PEGUNIGALSIDASE ALFA）每4周2 mg/kg给药方案的负面意见，同时与Protalix BioTherapeutics共同寻求对此持否定态度的重新审查。现有的Elfabrio市场授权依然生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2573983236","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 下午盘股价大涨5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573983236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573983236?lang=zh_cn&edition=full","pubTime":"2025-10-07 02:09","pubTimestamp":1759774187,"startTime":"0","endTime":"0","summary":"北京时间2025年10月07日02时09分，Protalix Biotherapeutics, Inc. 股票出现波动，股价快速拉升5.35%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为0.43%。其相关个股中，Leap Therapeutics, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Kalaris Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Leap Therapeutics, Inc.、Cdt Equity Inc.较为活跃，换手率分别为474.88%、216.68%、143.27%，振幅较大的相关个股有Leap Therapeutics, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Moolec Science Sa C/Wts ，振幅分别为61.63%、56.38%、50.94%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251007020947a6af0b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251007020947a6af0b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2570080102","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘急速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570080102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570080102?lang=zh_cn&edition=full","pubTime":"2025-09-25 03:39","pubTimestamp":1758742759,"startTime":"0","endTime":"0","summary":"北京时间2025年09月25日03时39分，Protalix Biotherapeutics, Inc. 股票出现波动，股价大幅拉升5.10%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，Uniqure N.V.、Tnf Pharmaceuticals, Inc.、Akari Therapeutics Plc涨幅较大，Tnf Pharmaceuticals, Inc.、Cyclerion Therapeutics, Inc.、Uniqure N.V.较为活跃，换手率分别为3194.88%、442.20%、121.12%，振幅较大的相关个股有Tnf Pharmaceuticals, Inc.、Uniqure N.V.、Akari Therapeutics Plc，振幅分别为135.04%、103.15%、60.49%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925033919a69be85e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925033919a69be85e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2514373584","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘大幅下跌5.15%报2.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514373584?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:35","pubTimestamp":1740753342,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时35分，Protalix Biotherapeutics, Inc. 股票出现波动，股价快速下跌5.15%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Enveric Biosciences, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Virpax Pharmaceuticals, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为492.73%、249.70%、156.36%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Enveric Biosciences, Inc.、Anaptysbio, Inc.，振幅分别为31.14%、27.83%、16.10%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822354298967ae3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822354298967ae3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2512616126","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大跌5.02%报2.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512616126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512616126?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:28","pubTimestamp":1739892514,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时28分，Protalix Biotherapeutics, Inc. 股票出现异动，股价快速下跌5.02%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为363.37%、156.72%、137.36%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 ，振幅分别为148.75%、79.17%、51.40%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328349627a26a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328349627a26a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2509258027","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509258027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509258027?lang=zh_cn&edition=full","pubTime":"2025-02-06 03:32","pubTimestamp":1738783942,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日03时32分，Protalix Biotherapeutics, Inc. 股票出现异动，股价急速上涨5.16%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为2.41%。其相关个股中，Invivyd, Inc.、Transcode Therapeutics, Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4639.31%、2353.35%、1754.71%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Invivyd, Inc.，振幅分别为132.24%、99.51%、69.59%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206033222abc3bc29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206033222abc3bc29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2507250375","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 急速上涨5.38%报2.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507250375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507250375?lang=zh_cn&edition=full","pubTime":"2025-01-29 04:42","pubTimestamp":1738096929,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日04时42分，Protalix Biotherapeutics, Inc. 股票出现波动，股价快速上涨5.38%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为0.12%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012904421096131c10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012904421096131c10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2506588593","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 急速下跌5.28%报2.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506588593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506588593?lang=zh_cn&edition=full","pubTime":"2025-01-28 01:29","pubTimestamp":1737998941,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日01时29分，Protalix Biotherapeutics, Inc. 股票出现波动，股价急速下跌5.28%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为1.06%。其相关个股中，Akero Therapeutics, Inc.、Dogwood Therapeutics, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Dogwood Therapeutics, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为2103.25%、858.03%、248.62%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为108.60%、85.35%、65.16%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128012901abba8474&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128012901abba8474&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2505029988","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505029988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505029988?lang=zh_cn&edition=full","pubTime":"2025-01-24 04:42","pubTimestamp":1737664973,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日04时42分，Protalix Biotherapeutics, Inc. 股票出现异动，股价大幅拉升5.06%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为1.86%。其相关个股中，Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Transcode Therapeutics, Inc.涨幅较大，Hepion Pharmaceuticals, Inc.、Dogwood Therapeutics, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为7526.36%、7515.98%、1290.26%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Transcode Therapeutics, Inc.、Nutriband Inc C/Wts ，振幅分别为948.57%、261.32%、172.73%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124044253960e878a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124044253960e878a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2505204100","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505204100","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505204100?lang=zh_cn&edition=full","pubTime":"2025-01-22 01:35","pubTimestamp":1737480925,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日01时35分，Protalix Biotherapeutics, Inc. 股票出现波动，股价急速上涨5.41%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为2.01%。其相关个股中，Dogwood Therapeutics, Inc.、Camp4 Therapeutics Corporation、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com涨幅较大，Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃，换手率分别为791.45%、506.92%、187.49%，振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.，振幅分别为96.32%、41.33%、38.48%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122013525abb36e43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122013525abb36e43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2503828105","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘急速下挫5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503828105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503828105?lang=zh_cn&edition=full","pubTime":"2025-01-14 00:04","pubTimestamp":1736784272,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日00时04分，Protalix Biotherapeutics, Inc. 股票出现异动，股价大幅下挫5.29%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体跌幅为1.04%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为11054.97%、5944.38%、422.33%，振幅较大的相关个股有Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.，振幅分别为336.09%、216.61%、124.54%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140004329864e697&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140004329864e697&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2501560332","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.18%报2.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501560332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501560332?lang=zh_cn&edition=full","pubTime":"2025-01-06 22:35","pubTimestamp":1736174120,"startTime":"0","endTime":"0","summary":"北京时间2025年01月06日22时35分，Protalix Biotherapeutics, Inc. 股票出现异动，股价快速拉升5.18%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，Scisparc Ltd.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Scisparc Ltd.、Cns Pharmaceuticals, Inc.、Aditxt, Inc.较为活跃，换手率分别为438.24%、219.87%、54.55%，振幅较大的相关个股有Scisparc Ltd.、Renovaro Inc.、Cns Pharmaceuticals, Inc.，振幅分别为32.18%、21.60%、15.20%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010622352095fa7361&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010622352095fa7361&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2500909178","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500909178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500909178?lang=zh_cn&edition=full","pubTime":"2025-01-03 04:17","pubTimestamp":1735849059,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日04时17分，Protalix Biotherapeutics, Inc. 股票出现异动，股价快速上涨5.26%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中，整体涨幅为0.46%。Protalix Biotherapeutics, Inc. 公司简介：Protalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103041739985940f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103041739985940f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protalix.com","stockEarnings":[{"period":"1week","weight":-0.2578},{"period":"1month","weight":-0.3039},{"period":"3month","weight":0.2171},{"period":"6month","weight":0.034},{"period":"1year","weight":-0.1446},{"period":"ytd","weight":0.1833}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protalix Biotherapeutics, Inc.最初于1992年4月在佛罗里达州注册成立，并于2016年3月在特拉华州重新注册。该公司是一家商业化阶段的生物制药公司，专注于利用其专有的植物细胞蛋白表达系统ProCellEx为罕见病开发和商业化创新疗法。它拥有两款已获批产品，用于治疗戈谢病的Elelyso和用于治疗法布里病的Elfabrio，分别通过与辉瑞和凯西的合作进行商业化。","yearOnYearQuotes":[{"month":1,"riseRate":0.736842,"avgChangeRate":0.12158},{"month":2,"riseRate":0.421053,"avgChangeRate":0.054153},{"month":3,"riseRate":0.315789,"avgChangeRate":-0.045486},{"month":4,"riseRate":0.578947,"avgChangeRate":0.056427},{"month":5,"riseRate":0.210526,"avgChangeRate":-0.051275},{"month":6,"riseRate":0.421053,"avgChangeRate":-0.034716},{"month":7,"riseRate":0.368421,"avgChangeRate":-0.04582},{"month":8,"riseRate":0.368421,"avgChangeRate":-0.012213},{"month":9,"riseRate":0.421053,"avgChangeRate":0.05112},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.052252},{"month":11,"riseRate":0.368421,"avgChangeRate":-0.008211},{"month":12,"riseRate":0.421053,"avgChangeRate":-0.008649}],"exchange":"AMEX","name":"Protalix BioTherapeutics Inc","nameEN":"Protalix BioTherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protalix BioTherapeutics Inc(PLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Protalix BioTherapeutics Inc(PLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Protalix BioTherapeutics Inc,PLX,Protalix BioTherapeutics Inc股票,Protalix BioTherapeutics Inc股票老虎,Protalix BioTherapeutics Inc股票老虎国际,Protalix BioTherapeutics Inc行情,Protalix BioTherapeutics Inc股票行情,Protalix BioTherapeutics Inc股价,Protalix BioTherapeutics Inc股市,Protalix BioTherapeutics Inc股票价格,Protalix BioTherapeutics Inc股票交易,Protalix BioTherapeutics Inc股票购买,Protalix BioTherapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protalix BioTherapeutics Inc(PLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Protalix BioTherapeutics Inc(PLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}